I-131 Mini

Generic name: sodium iodide i-131
Dosage form: capsule
Drug classes:Antithyroid agents, Therapeutic radiopharmaceuticals

Medically reviewed by Drugs.com. Last updated on Apr 21, 2022.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Dear Medical Professional, Per your order, we have compounded I-131 in Mini Cap form. The characteristics of this compound are:

I-131 Mini Description

Sodium Iodide I-131 (NaI-131) for therapeutic use is supplied for oral administration in small opaque white gelatin capsules, inside a blue and clear outer capsule. Each I-131 Mini capsule is available in strengths ranging from (0.1 – 150 mCi) at the time of calibration. Iodine 131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days.

Sodium Iodide I-131 Mini Capsules are compounded by absorbing a solution of carrier-free sodium iodide I-131 into inert filler. The iodine 131 utilized in the preparation of the capsules contains not less than 99% Iodine-131 at the time of calibration.

Gelatin capsules are compounded per prescription requirements using high specific concentration I-131, allowing higher iodine activity in a small easy to swallow high activity capsule size. Capsules are formulated to rapidly dissolve in saline solution, to allow use for oral solution administration when clinically necessary.

CONTRAINDICATIONS AND ADVERSE REACTIONS

Radioiodine is excreted in human milk during lactation; breast feeding must be substituted during and following dose administration. Sodium Iodide 131 is not usually used for treatment of hyperthyroidism in patients under 30 years of age. Reactions to administration are rare; however potential side effects such as radiation sickness and bone marrow depression, acute leukemia, anemia, chromosomal abnormalities, acute thyroid crisis, blood dyscrasia, leukopenia, thrombocytopenia, and death represent potential side effects.

I-131 Mini Dosage and Administration

Anti-thyroid therapy of a severely hyperthyroid patient is usually discontinued three to four days before administration of radioiodide. For hyperthyroidism, the usual dose range is 4 to 10 mCi. Toxic nodular goiter and other special situations will require the use of larger doses. For thyroid carcinoma, 50 mCi is the usual dose for ablation of normal thyroid tissue, and 100 to 150 mCi is the usual subsequent therapeutic dose. Waterproof gloves should be used during the entire handling and administration procedure. Adequate shielding must be maintained.

CLINICAL UTILITY

Most patients with thyroid disease present with a thyroid nodule. Tools utilized to assess thyroid nodules and to rule out thyroid cancer include: serum thyroid function tests (TSH and thyroid hormone lev...